Trials / Completed
CompletedNCT05352867
Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People
Phase Ⅱ Clinical Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18~59 Years
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 420 (actual)
- Sponsor
- AIM Vaccine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
Phase Ⅱ Clinical Trial to Evaluate the Safety and Immunogenicity of the New Coronavirus mRNA Vaccine (LVRNA009) in Chinese People Aged 18\~59 Years
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SARS-CoV-2 (LVRNA009) 50μg group | 50μg/person |
| BIOLOGICAL | SARS-CoV-2 (LVRNA009) 100μg group | 100μg/person |
| OTHER | Placebo | 0.5ml/person |
Timeline
- Start date
- 2022-03-16
- Primary completion
- 2022-06-23
- Completion
- 2023-06-21
- First posted
- 2022-04-29
- Last updated
- 2023-09-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05352867. Inclusion in this directory is not an endorsement.